
Izvēlieties etiķeti
redzama tieši uz flakonaBPC + TB Oral Blend
Healing Oral
- Sūtām no Vācijas
Pasūtījums
- DHL ar izsekošanu
- Diskrēts iepakojums
Īsumā
BPC + TB Oral Blend skaitļos
Galvenie rādītāji no mūsu leksikona.
Pilns leksikona ieraksts- Class
- Oral healing blendBPC + TB
- Use
- Oraltablet
- Sizes
- 1 mg1 size in the shop
What studies show
The source in the lexicon- Crockford et al., Annals of the New York Academy of Sciences, 2010
Produktam BPC + TB Oral Blend vēl nav laboratorijas analīzes. Balsot par toPasūtiet testu, mēs apmaksājam pusiVisas laboratorijas analīzes
Zināšanas
Viss par BPC + TB Oral Blend
Detalizēta informācija drīzumā.
Are there studies on this tablet?
No. As of 26 October 2026 there is no study of BPC-157 and TB-500 together taken by mouth, neither on ClinicalTrials.gov nor in PubMed. Everything here comes from studies on the single compounds.
Do both work better together?
That is not established. In the only study of both peptides together (Achilles tendon in 32 rats, injected into the abdominal cavity) each on its own was linked to better tendon tissue, significantly above all with TB-500, which also raised tensile strength. The combination gave no advantage over either alone. The authors suspect shared signalling pathways.
What is TB-500?
TB-500 is sold as a fragment of thymosin beta-4. Thymosin beta-4 binds the structural protein actin in cells and is linked to cell migration, new vessel formation and tissue repair. A 2026 review finds hardly any solid human safety data for TB-500.
Are the peptides absorbed by mouth?
For BPC-157 there are hints from animal studies: according to a review it is stable in human gastric juice and worked via the drinking water in rats. There are no blood measurements after oral dosing. For TB-500 by mouth there are no data at all.
Which trials are running on the components?
As of 26 October 2026 no trial in which a component is injected is recruiting. Announced are a phase 1 trial of BPC-157 under the skin after shoulder surgery and a third phase 2 trial of thymosin beta-4 after heart attack. Two phase 2 trials of thymosin beta-4 after heart attack are completed. A study of gummies with BPC-157 is completed, results are still missing.
Which side effects are known?
None for the tablet. No treatment-related side effects occurred in the three small human studies on BPC-157, but the certainty is very low. 40 healthy people tolerated thymosin beta-4 into a vein without serious side effects. One review warns of risks from unregulated manufacturing.
Saistītie
Saistītie produkti
BPC + TB Oral Blend